Ozanimod | Sphingosine-1-phosphate receptor agonist

CAS:
 1306760-87-1
Catalog Number:
 10-3739
Ozanimod chemical structure

Available Options

Size:PriceQuantity 
5 mg$55.00
25 mg$200.00
Request Quote / Bulk / Custom Size
Product Inquiry

Ozanimod (1306760-87-1) binds to human recombinant sphingosine-1-phosphate receptor S1P1 and S1P5 receptors in a competitive radioligand binding assay. Agonism at S1P1 receptors induced receptor internalization whereas S1P5 did not.1 It displays anti-inflammatory activity and is in clinical use for multiple sclerosis2 and inflammatory bowel disease3. It reduces chronic inflammation and alleviates kidney pathology in systemic lupus erythematosus in a mouse model.4

References/Citations:

  1. Selkirk et al. (2023), In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors; Eur. J. Pharmacol., 941 175442
  2. Ziemssen et al. (2022), OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany; Front. Neurol., 13 913616
  3. Massironi et al. (2024), Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials; J. Gastroenterol., 59 761
  4. Meadows et al. (2018), Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus; PLoS One, 13 e0193236
1306760-87-1, ozanimod, Ozanimod supplier, RPC1063, S1P1 agonist, S1P5 agonist
CAS:
1306760-87-1
Catalog Number:
10-3739
Activity:
Sphingosine-1-phosphate receptor agonist
Chemical Names:
5-[3-[(1S)-2,3-Dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)-benzonitrile
Alternate Name:
RPC1063
Molecular Weight:
404.47
Molecular Formula:

C23H24N4O3

Solubility:
Soluble in DMSO (5 mg/ml with warming)
Physical Properties:
White solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months. Product is hygroscopic.
Shipping Code:
RT

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Ozanimod (1306760-87-1) binds to human recombinant sphingosine-1-phosphate receptor S1P1 and S1P5 receptors in a competitive radioligand binding assay. Agonism at S1P1 receptors induced receptor internalization whereas S1P5 did not.1 It displays anti-inflammatory activity and is in clinical use for multiple sclerosis2 and inflammatory bowel disease3. It reduces chronic inflammation and alleviates kidney pathology in systemic lupus erythematosus in a mouse model.4

References/Citations:

  1. Selkirk et al. (2023), In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors; Eur. J. Pharmacol., 941 175442
  2. Ziemssen et al. (2022), OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany; Front. Neurol., 13 913616
  3. Massironi et al. (2024), Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials; J. Gastroenterol., 59 761
  4. Meadows et al. (2018), Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus; PLoS One, 13 e0193236

STEM CELL

BOGO